VivoSim Labs Inc (VIVS) Stock Analysis

Verdict: AVOID

A 7-figure pharma deal sparks a 142.9% rally, but $10.8M annual cash burn vs $5.02M cash poses severe dilution risk.

Investment score: 31/100

Analysis as of

Is VivoSim Labs Inc stock worth reviewing? The TradeMates thesis

The TradeMates model assigns an AVOID recommendation with an investment score of 31/100 due to severe cash burn and negative equity despite recent positive contract momentum.

7-factor investment score

VivoSim Labs Inc opportunities and risks

What speaks for VIVS

What speaks against VIVS

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
VIVSn/a35.8x0.3x-162.2%-7605.9%-212.7%
ERNAn/a0.0x0.1x0.0%0.0%-389.8%
DRMAn/a35.4x0.2x54.1%-12811.5%-344.8%
ORGSn/a0.4xn/a-1080.2%-10445.5%-8639.7%
ONCOn/a2.5x0.0x73.8%-7423.9%-781.3%
PMCBn/a0.0x2.8x0.0%0.0%-152.9%
Peer mediann/a0.4x0.1x0.0%-7423.9%-389.8%

Frequently asked questions about VivoSim Labs Inc (VIVS)

Is VIVS stock a good investment?

The TradeMates model rates VivoSim Labs Inc as AVOID with an investment score of 31/100. The TradeMates model assigns an AVOID recommendation with an investment score of 31/100 due to severe cash burn and negative equity despite recent positive contract momentum. This is algorithmic model output, not personal investment advice.

Is VIVS stock a buy?

The TradeMates model verdict for VIVS is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.